Unlock instant, AI-driven research and patent intelligence for your innovation.

Multistage process for preparation of highly pure deferoxamine mesylate salt

A technology of mesylate and deferoxamine, applied in the field of preparation of high-purity deferoxamine B mesylate, can solve problems such as overestimation of deferoxamine

Inactive Publication Date: 2003-07-30
BIOGAL PHARMA CO LTD
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Also, structurally related impurities can form complexes that absorb in the 485 nm range, leading to an overestimation of deferoxamine B content

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0049] Crude deferoxamine B hydrochloride (7.88 kg) containing 5.30 kg of deferoxamine B was dissolved in water (362 L). Then at 14Lh -1 At a flow rate, pass the aqueous solution through an equal volume of Diaion packed in a 10-liter column  SP 207 adsorption resin (Mitsubishi Chemical Corp.). The eluate contained 5.04 kg deferoxamine. Then, stir with 5gL -1 The amount of ammonium chloride was added to the eluent until the ammonium chloride was completely dissolved. The solution was then loaded into the Amberlite-containing  XAD 1180 adsorption resin (132 L) (Rohm & Haas) was applied to a column and the bed was eluted with brine. The column was first eluted with 10% acetonitrile-water, then in 14Lh -1 Elute with 20% acetonitrile-water at a constant flow rate. Collect eluate fractions. The main fraction yielded a solution of deferoxamine hydrochloride containing 4.53 kg of deferoxamine B. The main fraction was then treated with activated carbon (45 g) and H + Form D...

Embodiment 2

[0053] Crude deferoxamine B hydrochloride (707 g) containing 587 g of deferoxamine B was dissolved in water (10 L). Then at 0.35Lh -1 At a flow rate, pass the aqueous solution through the  Column with SP 207 Adsorbent Resin (1L). The eluate from the column was found to contain 562 grams of deferoxamine B. The eluent is then loaded onto the Amberlite packed in a column  A bed of XAD 1180 adsorbent resin (7.2 L). First use 5.6L with a concentration of 10gL -1 Ammonium chloride aqueous solution in 0.7Lh -1 The bed was eluted at flow rate and then with a 1:4 methanol-water mixture. A single fraction of deferoxamine B (432 g) was collected. Fractions were decolorized by stirring with charcoal (40 g) and filtered. Evaporate the eluate after decolorization so that the concentration of deferoxamine B is 60gL -1 .

[0054] An equal amount of acetonitrile was then added. Concentrated aqueous ammonia was then added until the pH of the solution reached 9.8. 4 times the amoun...

Embodiment 3

[0056] Crude deferoxamine B hydrochloride (760 g) containing 530 g of deferoxamine B was dissolved in 1:1 acetonitrile-water (14 L) at 40°C. The resulting solution was then filtered and the pH was adjusted to 9.9 by the addition of concentrated aqueous ammonia. Acetonitrile (49 L) was added to precipitate deferoxamine B free base. The resulting suspension was cooled to 17°C and maintained at reduced temperature for 4 hours. The precipitate was isolated by filtration, washed with acetonitrile, and dried under reduced pressure to give deferoxamine B free base (403 g). The base was then suspended in water (20 L) and hydrochloric acid was added slowly until the base dissolved and the pH of the resulting solution reached 5.0-5.5.

[0057] Load the solution onto the Amberlite packed in a column  XAD 1180 was adsorbed onto the bed of resin (7.2 L) and eluted with 25% acetonitrile-water. A single fraction of deferoxamine B (320 g) was obtained. The eluate containing deferoxamine...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a purification process whereby deferoxamine B produced by a microorganism and in mixture with other polyhydroxamates produced by the microorganism may be converted into its mesylate salt substantially free of the other polyhydroxamates and substantially free of chloride ion. The process includes adsorption and desorption of the deferoxamine B on an adsorption resin, direct precipitation of the deferoxamine free base out of the eluent from the adsorption resin, contacting of the deferoxamine B free base with methanesulfonic acid and isolation of the deferoxamine B mesylate salt by precipitation. This process minimizes decomposition of deferoxamine B.

Description

[0001] related application [0002] This application claims priority under 35 U.S.C. §119 to Hungarian patent application P 99 04454 filed December 1, 1999. field of invention [0003] The invention relates to a method for preparing high-purity deferoxamine B mesylate. Background of the invention [0004] Deferoxamine B, represented by formula I, is a polyhydroxamate iron chelator useful for reducing iron concentrations in human plasma. [0005] The systematic chemical name of deferoxamine B (also known as deferriferrioxamine B) is N'-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxabutyl ]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxysuccinamide. Desferoxamine B has a desirably high affinity for ferric iron (Ka=10 31 ) and very low affinity for calcium (Ka=10 2 ). See, Goodman and Gilman, The Pharmacological Basis of Therapeutics 1668 (9th ed., 1996). [0006] It has been noted that deferoxamine B is useful in the management of acute iron poisoning and chroni...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12P13/02C07C259/06
CPCC07C259/06
Inventor V·克里Z·措维克A·梅佐
Owner BIOGAL PHARMA CO LTD